Berenberg Raises Roche Price Target Amid Higher Breast Cancer Treatment Sales Peak Forecast

06:09 AM EST, 12/18/2025 (MT Newswires) -- Berenberg lifted the price target for Roche (ROG.SW) to 320 francs from 300 francs, raising its peak sales forecast for the pharmaceutical company's breast cancer treatment giredestrant to 11 billion francs from 6 billion francs. The Swiss stock's hold rating was also reiterated on Thursday as the investigational adjuvant endocrine treatment is already reflected in the research firm's valuation. "Highly positive lidERA data for giredestrant in adjuvant breast cancer support use in the c15% of patients who are medium/high risk with stage I disease or stage II/III and ineligible for CDK4/6 inhibitors," analysts wrote. "Attention now turns to giredestrant's 1L persevERA readout in Q1 2026 and sub-group data from lidERA on the giredestrant+Verzenio combination (due end 2026) for further upside to forecasts."